Abstract
Deaths from tuberculosis (TB) reached over 1.6 million in 2021 with 10.6 million people becoming ill. Multidrug-resistant TB, defined as theMycobacterium tuberculosisorganism having resistance to at least isoniazid and rifampicin, represented 3.9% of new TB cases and 18% of previously treated cases. While new drug regimens continue to be developed and introduced to improve treatment of drug-resistant forms of TB, diagnostic capability to identify drug resistance lags woefully behind. While significant mortality benefits exist for these newer drug regimens, implementing them without proper drug resistance diagnostic capacity could lead to development of more drug resistances and exhaust these new therapeutic tools. Moving forward, the roll-out of new TB drugs and regimens must be paired with implementation of diagnostics to ensure judicious use of resources and the best chance for improving TB worldwide.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference23 articles.
1. World Health Organization . Global tuberculosis report 2021. Date last updated: 14 October 2021. www.who.int/publications/i/item/9789240037021
2. World Health Organization . WHO announces updated definitions of extensively drug-resistant tuberculosis. Date last updated: 27 January 2021. www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis
3. World Health Organization . WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Date last updated: 21 September 2022. www.who.int/publications/i/item/9789240046764
4. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis – United States, 2022;Carr;MMWR Morb Mortal Wkly Rep,2022
5. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis